Prognia
Drug Database
🇪🇺EU · EMAAuthorisedATC: J07BN

Bimervax(SARS-CoV-2 virus recombinant spike (S) protein receptor binding domain (RBD) fusion dimer produced by recombinant DNA technology)

COVID-19 virus infection

Marketing Authorisation Holder: Hipra Human Health S.L.

EMA Authorisation: 30/03/2023

INN: COVID-19 Vaccine (recombinant, adjuvanted)

Indication

Bimervax is indicated as a booster for active immunisation to prevent COVID-19 in individuals 12 years of age and older who have previously received a mRNA COVID-19 vaccine (see sections 4.2 and 5.1). The use of this vaccine should be in accordance with official recommendations. Bimervax XBB.1.16 is indicated for active immunisation to prevent COVID-19 caused by SARS-CoV-2 in individuals 12 years of age and older. The use of this vaccine should be in accordance with official recommendations. Bimervax LP.8.1 is indicated for active immunisation to prevent COVID-19 caused by SARS CoV-2 in individuals 12 years of age and older. The use of this vaccine should be in accordance with official recommendations.

Official EMA Resources

View on EMA (ema.europa.eu)

AI Drug & Interaction Analysis

Free account required

Ask Prognia AI about Bimervax — dosing recommendations, drug interactions, and current guideline evidence from ESC, EMA, NICE and more.

Ask about BimervaxCreate Free Account

Medical disclaimer: This information is intended for qualified healthcare professionals. Always verify with the official EMA Summary of Product Characteristics (SmPC) before clinical use.